BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005;100:56-63. [PMID: 15654781 DOI: 10.1111/j.1572-0241.2005.40670.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 108] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Ioannou GN, Beste LA, Green PK. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol. 2014;12:1371-1380. [PMID: 24361415 DOI: 10.1016/j.cgh.2013.12.011] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
2 Sherman M, Cohen L, Cooper MA, Elkashab M, Feinman V, Fletcher D, Girgrah N, Heathcote J, Levstik M, McNaull WB, Wong D, Wong F, Yim C. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-85. [PMID: 16858501 DOI: 10.1155/2006/497059] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
3 Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, Renou C, Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Alimentary Pharmacology & Therapeutics 2009;30:61-70. [DOI: 10.1111/j.1365-2036.2009.03995.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
4 Kowalkowski MA, Mims MA, Day RS, Du XL, Chan W, Chiao EY. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans. Cancer Epidemiol 2014;38:386-92. [PMID: 24947588 DOI: 10.1016/j.canep.2014.05.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
5 Henderson WA, Shankar R, Gill JM, Kim KH, Ghany MG, Skanderson M, Butt AA. Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 2010;17:59-64. [PMID: 19566787 DOI: 10.1111/j.1365-2893.2009.01151.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
6 Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, Semaille C. Burden of HIV and hepatitis C co-infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 2015;35:65-70. [PMID: 25040895 DOI: 10.1111/liv.12639] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
7 Nagao A, Hanabusa H. Brief Report: The Impact of Ledipasvir/Sofosbuvir on HIV-Positive and HIV-Negative Japanese Hemophilia Patients With 1, 4, and Mixed-Genotype HCV. J Acquir Immune Defic Syndr 2017;74:418-22. [PMID: 27984558 DOI: 10.1097/QAI.0000000000001271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
8 de Lédinghen V, Barreiro P, Foucher J, Labarga P, Castéra L, Vispo ME, Bernard PH, Martin-Carbonero L, Neau D, García-Gascó P. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat. 2008;15:427-433. [PMID: 18221303 DOI: 10.1111/j.1365-2893.2007.00962.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
9 Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, Rauch A, Probst-Hensch NM, Bouchardy C, Levi F, Franceschi S; Swiss HIV Cohort. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22:2135-41. [PMID: 18832877 DOI: 10.1097/QAD.0b013e32831103ad] [Cited by in Crossref: 117] [Cited by in F6Publishing: 63] [Article Influence: 8.4] [Reference Citation Analysis]
10 Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017;. [PMID: 28887168 DOI: 10.1016/j.jhep.2017.08.030] [Cited by in Crossref: 189] [Cited by in F6Publishing: 213] [Article Influence: 37.8] [Reference Citation Analysis]
11 Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Halfon P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02. Journal of Hepatology 2008;48:765-73. [DOI: 10.1016/j.jhep.2008.01.025] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
12 Swaminath A, Oliver DL, Mcneil AC, Hassanein TI. The influence of hiv coinfection on the natural history of hcv infection. Curr hepatitis rep 2005;4:131-7. [DOI: 10.1007/s11901-005-0028-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Mukhtar NA, Ness EM, Jhaveri M, Fix OK, Hart M, Dale C, Pratt C, Kowdley KV. Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States. Ann Hepatol 2019;18:360-5. [PMID: 31053542 DOI: 10.1016/j.aohep.2018.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ioannou GN, Beste LA, Chang MF, Green PK, Lowy E, Tsui JI, Su F, Berry K. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 2016; 151: 457-471. e5. [PMID: 27267053 DOI: 10.1053/j.gastro.2016.05.049] [Cited by in Crossref: 152] [Cited by in F6Publishing: 149] [Article Influence: 25.3] [Reference Citation Analysis]
15 Re VL, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel BS, Rennert H, Stieritz DD, Putt M, Frank I, Strom BL. Incidence and Risk Factors for Weight Loss During Dual HIV/Hepatitis C Virus Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes 2007;44:344-50. [DOI: 10.1097/qai.0b013e31802f12d3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
16 Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One 2018;13:e0204412. [PMID: 30260995 DOI: 10.1371/journal.pone.0204412] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
17 Butt AA, McGinnis K, Skanderson M, Justice AC. A comparison of treatment eligibility for hepatitis C virus in HCV-monoinfected versus HCV/HIV-coinfected persons in electronically retrieved cohort of HCV-infected veterans. AIDS Res Hum Retroviruses 2011;27:973-9. [PMID: 21338329 DOI: 10.1089/AID.2011.0004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
18 Yartel AK, Morgan RL, Rein DB, Ann Brown K, Kil NB, Massoud OI, Fallon MB, Smith BD. HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. Am J Prev Med 2015;49:423-7. [PMID: 25896194 DOI: 10.1016/j.amepre.2015.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Johnson K, Green PK, Ioannou GN. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C. J Viral Hepat 2017;24:966-75. [PMID: 28585416 DOI: 10.1111/jvh.12731] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
20 Shaltiel T, Zheng S, Siderides C, Gleeson EM, Carr J, Pletcher ER, Cohen NA, Golas BJ, Magge DR, Labow DM, Branch AD, Sarpel U. Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype. Cancer 2021;127:1395-406. [PMID: 33629759 DOI: 10.1002/cncr.33377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Deng LP, Gui XE, Zhang YX, Gao SC, Yang RR. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. World J Gastroenterol 2009; 15(8): 996-1003 [PMID: 19248201 DOI: 10.3748/wjg.15.996] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
22 Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015;373:705-13. [PMID: 26196665 DOI: 10.1056/NEJMoa1501315] [Cited by in Crossref: 354] [Cited by in F6Publishing: 154] [Article Influence: 50.6] [Reference Citation Analysis]
23 Gramenzi A, Tedeschi S, Cantarini MC, Erroi V, Tumietto F, Attard L, Calza L, Foschi FG, Caraceni P, Pavoni M, Cucchetti A, Bernardi M, Viale P, Verucchi G, Trevisani F. Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Digestive and Liver Disease 2013;45:516-22. [DOI: 10.1016/j.dld.2012.12.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
24 Su F, Cogan CJ, Bendich I, Zhang N, Whooley MA, Kuo AC. Hepatitis C infection and complication rates after total shoulder arthroplasty in United States veterans. JSES Int 2021;5:699-706. [PMID: 34223418 DOI: 10.1016/j.jseint.2021.02.009] [Reference Citation Analysis]
25 Rosenthal E, Salmon-céron D, Lewden C, Bouteloup V, Pialoux G, Bonnet F, Karmochkine M, May T, François M, Burty C, Jougla E, Costagliola D, Morlat P, Chêne G, Cacoub P; the Mortavic/Mortalité 2005 Study Group. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Medicine 2009;10:282-9. [DOI: 10.1111/j.1468-1293.2008.00686.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 6.1] [Reference Citation Analysis]
26 Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, Galindo L, García-Gascó P, García-Samaniego J, Soriano V. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat. 2008;15:165-172. [PMID: 18233989 DOI: 10.1111/j.1365-2893.2007.00903.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 0.5] [Reference Citation Analysis]
27 Beste LA, Green P, Berry K, Belperio P, Ioannou GN. Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. JAMA 2020;324:1003-5. [PMID: 32897335 DOI: 10.1001/jama.2020.10121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
28 Monto A, Kakar S, Dove LM, Bostrom A, Miller EL, Wright TL. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients. Am J Gastroenterol 2006;101:1509-15. [PMID: 16863554 DOI: 10.1111/j.1572-0241.2006.00613.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
29 Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer. 2009;125:1755-1763. [PMID: 19588503 DOI: 10.1002/ijc.24741] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
30 Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, Richardson P, El-Serag HB. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-1188.e1. [PMID: 21184757 DOI: 10.1053/j.gastro.2010.12.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 258] [Article Influence: 22.1] [Reference Citation Analysis]
31 Rosenthal E, Roussillon C, Salmon-Céron D, Georget A, Hénard S, Huleux T, Gueit I, Mortier E, Costagliola D, Morlat P. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalité 2010 survey. HIV Med. 2015;16:230-239. [PMID: 25522874 DOI: 10.1111/hiv.12204] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
32 Mun EJ, Green P, Berry K, Ioannou GN. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. Eur J Gastroenterol Hepatol 2019;31:47-52. [PMID: 30142097 DOI: 10.1097/MEG.0000000000001242] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol 2013;24:217-38. [PMID: 24489565 DOI: 10.1155/2013/781410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
34 Lerrigo R, Beste LA, Leipertz SL, Green PK, Lok AS, Kogut MJ, Ioannou GN. Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System. Eur J Gastroenterol Hepatol 2016;28:667-75. [PMID: 26886386 DOI: 10.1097/MEG.0000000000000604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
35 Kew MC. Hepatocellular carcinoma in African Blacks: Recent progress in etiology and pathogenesis. World J Hepatol 2010; 2(2): 65-73 [PMID: 21160975 DOI: 10.4254/wjh.v2.i2.65] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
36 Luo R, Greenberg A, Stone CD. Increasing Volume but Decreasing Mortality of Hospitalized Hepatitis C Patients in the United States, 2005 to 2011. J Clin Gastroenterol 2015;49:620-7. [PMID: 25203363 DOI: 10.1097/MCG.0000000000000216] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Degos F, Tural C. Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: Is it really different, and if so, why? Journal of Hepatology 2007;47:447-50. [DOI: 10.1016/j.jhep.2007.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
38 Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology. 2019;157:1264-1278.e4. [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 31.7] [Reference Citation Analysis]
39 Clifford GM, Franceschi S. Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol 2009;5:669-78. [PMID: 19519206 DOI: 10.2217/fon.09.28] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
40 Mahure SA, Bosco JA, Slover JD, Vigdorchik JM, Iorio R, Schwarzkopf R. Coinfection with Hepatitis C and HIV Is a Risk Factor for Poor Outcomes After Total Knee Arthroplasty. JB JS Open Access 2017;2:e0009. [PMID: 30229221 DOI: 10.2106/JBJS.OA.17.00009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
41 Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology. 2018;155:1128-1139.e6. [PMID: 29981779 DOI: 10.1053/j.gastro.2018.06.079] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
42 Butt AA, Justice AC, Skanderson M, Good C, Kwoh CK. Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther. 2006;24:585-591. [PMID: 16907891 DOI: 10.1111/j.1365-2036.2006.03020.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
43 Merchante N, Merino E, López-Aldeguer J, Jover F, Delgado-Fernández M, Galindo MJ, Ortega E, Rivero A, Mínguez C, Romero-Palacios A, Padilla S, Márquez-Solero M, Amador C, Ríos-Villegas MJ, Téllez F, Portilla J, Pineda JA. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56:143-50. [PMID: 22955438 DOI: 10.1093/cid/cis777] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
44 Mahure SA, Bosco JA, Slover JD, Vigdorchik J, Iorio R, Schwarzkopf R. Risk of Complications After THA Increases Among Patients Who Are Coinfected With HIV and Hepatitis C. Clin Orthop Relat Res 2018;476:356-69. [PMID: 29529669 DOI: 10.1007/s11999.0000000000000025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
45 Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007;56:385-9. [PMID: 17005764 DOI: 10.1136/gut.2006.099150] [Cited by in Crossref: 115] [Cited by in F6Publishing: 119] [Article Influence: 7.7] [Reference Citation Analysis]
46 Cooper CL. An Overview of HIV and Chronic Viral Hepatitis Co-Infection. Dig Dis Sci 2008;53:899-904. [DOI: 10.1007/s10620-007-0134-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Zevallos JP, Kramer JR, Sandulache VC, Massa ST, Hartman CM, Mazul AL, Wahle BM, Gerndt SP, Sturgis EM, Chiao EY. National trends in oropharyngeal cancer incidence and survival within the Veterans Affairs Health Care System. Head Neck 2021;43:108-15. [PMID: 32918302 DOI: 10.1002/hed.26465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012;24:506-16. [PMID: 22759737 DOI: 10.1097/CCO.0b013e328355e131] [Cited by in Crossref: 76] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
49 Valle Tovo C, Alves de Mattos A, Ribeiro de Souza A, Ferrari de Oliveira Rigo J, Lerias de Almeida PR, Galperim B, Riegel Santos B. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus. Liver Int 2007;27. [DOI: 10.1111/j.1478-3231.2006.01344.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
50 Ioannou GN, Bryson CL, Weiss NS, Boyko EJ. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. Eur J Gastroenterol Hepatol 2015;27:577-84. [PMID: 25769096 DOI: 10.1097/MEG.0000000000000290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
51 Xiong H, Rong X, Wang M, Xu R, Huang K, Liao Q, Huang J, Chen J, Li C, Tang X, Shan Z, Zhang M, Nelson K, Fu Y. HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China. J Viral Hepat 2017;24:312-9. [PMID: 27943542 DOI: 10.1111/jvh.12644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
52 Hu J, Liu K, Luo J. HIV-HBV and HIV-HCV Coinfection and Liver Cancer Development. Cancer Treat Res 2019;177:231-50. [PMID: 30523627 DOI: 10.1007/978-3-030-03502-0_9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
53 Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, des Jarlais D, Braithwaite RS. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clin Infect Dis 2020;70:2652-62. [PMID: 31400755 DOI: 10.1093/cid/ciz726] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Monto A, Currie S, Wright TL. Liver Disease in Injection Drug Users with Hepatitis C, With and Without HIV Coinfection. Journal of Addictive Diseases 2008;27:49-59. [DOI: 10.1300/j069v27n02_06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Hu J, Ludgate L. HIV-HBV and HIV-HCV coinfection and liver cancer development. Cancer Treat Res. 2007;133:241-252. [PMID: 17672044 DOI: 10.1007/978-0-387-46816-7_9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
56 Lavian JD, Murray DP, Hollern DA, Bloom L, Shah NV, Gewolb D, Segreto FA, Powell S, Messina JC, Naziri Q, Yoshihara H, Paulino CB, Diebo BG. The Risks of Hepatitis C in Association With Cervical Spinal Surgery: Analysis of Radiculopathy and Myelopathy Patients. Clin Spine Surg 2018;31:86-92. [PMID: 29293101 DOI: 10.1097/BSD.0000000000000606] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Moon AM, Green PK, Berry K, Ioannou GN. Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Aliment Pharmacol Ther 2017;45:1201-12. [PMID: 28271521 DOI: 10.1111/apt.14021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
58 Macdonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14(11): 1657-1663 [PMID: 18350596 DOI: 10.3748/wjg.14.1657] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
59 Yan Y, Huang F, Yuan T, Sun B, Yang R. HIV-1 Vpr increases HCV replication through VprBP in cell culture. Virus Research 2016;223:153-60. [DOI: 10.1016/j.virusres.2016.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-432. [PMID: 17597707 DOI: 10.1038/ncponc0844] [Cited by in Crossref: 191] [Cited by in F6Publishing: 179] [Article Influence: 12.7] [Reference Citation Analysis]
61 Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, Tapper EB, Singal AG, Zhu J, Waljee AK. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Netw Open. 2020;3:e2015626. [PMID: 32870314 DOI: 10.1001/jamanetworkopen.2020.15626] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
62 Seaberg EC, Wiley D, Martínez-Maza O, Chmiel JS, Kingsley L, Tang Y, Margolick JB, Jacobson LP; Multicenter AIDS Cohort Study (MACS). Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010;116:5507-16. [PMID: 20672354 DOI: 10.1002/cncr.25530] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 9.4] [Reference Citation Analysis]
63 Bruyand M, Dabis F, Vandenhende M, Lazaro E, Neau D, Leleux O, Geffard S, Morlat P, Chêne G, Bonnet F. HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998–2008. Journal of Hepatology 2011;55:1058-62. [DOI: 10.1016/j.jhep.2011.02.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
64 Ocama P, Nambooze S, Opio CK, Shiels MS, Wabinga HR, Kirk GD. Trends in the incidence of primary liver cancer in Central Uganda, 1960-1980 and 1991-2005. Br J Cancer 2009;100:799-802. [PMID: 19174820 DOI: 10.1038/sj.bjc.6604893] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
65 Ananthakrishnan AN, McGinley EL, Fangman J, Saeian K. Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. J Viral Hepat. 2010;17:720-729. [PMID: 20002558 DOI: 10.1111/j.1365-2893.2009.01232.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
66 Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009;49:225-232. [PMID: 19508169 DOI: 10.1086/599371] [Cited by in Crossref: 175] [Cited by in F6Publishing: 184] [Article Influence: 13.5] [Reference Citation Analysis]
67 Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007;14:890-6. [PMID: 18070293 DOI: 10.1111/j.1365-2893.2007.00885.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 41] [Article Influence: 0.5] [Reference Citation Analysis]
68 Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend 2016;169:101-9. [PMID: 27810652 DOI: 10.1016/j.drugalcdep.2016.10.021] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
69 Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group., ANRS CO12 Cirvir study group. Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir). Clin Res Hepatol Gastroenterol 2012;36:214-21. [PMID: 22189509 DOI: 10.1016/j.clinre.2011.11.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
70 Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health 2011;8:512-20. [PMID: 22127037 DOI: 10.1071/SH10163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
71 Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008;26:474-479. [PMID: 18202423 DOI: 10.1200/jco.2007.14.2810] [Cited by in Crossref: 88] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
72 Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J, González-García JJ, Hernando A, Ortega E, Sanz J. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. J Acquir Immune Defic Syndr. 2014;65:82-86. [PMID: 24419065 DOI: 10.1097/qai.0b013e3182a685dc] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
73 Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008;27:274-282. [PMID: 17996017 DOI: 10.1111/j.1365-2036.2007.03572.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 190] [Article Influence: 12.3] [Reference Citation Analysis]
74 De Paoli P, Carbone A. Carcinogenic viruses and solid cancers without sufficient evidence of causal association. Int J Cancer. 2013;133:1517-1529. [PMID: 23280523 DOI: 10.1002/ijc.27995] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
75 Wang CC, Silverberg MJ, Abrams DI. Non-AIDS-Defining Malignancies in the HIV-Infected Population. Curr Infect Dis Rep 2014;16:406. [PMID: 24844467 DOI: 10.1007/s11908-014-0406-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
76 Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut 2021;70:370-8. [PMID: 32229544 DOI: 10.1136/gutjnl-2019-319867] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
77 Mitchell LR, Shah N, Selwyn PA. Palliative Care in the Management of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in the Primary Care Setting. Prim Care 2019;46:433-45. [PMID: 31375191 DOI: 10.1016/j.pop.2019.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
78 Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol 2017;67:32-9. [PMID: 28267622 DOI: 10.1016/j.jhep.2017.02.027] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 18.2] [Reference Citation Analysis]
79 Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018;69:1088-1098. [PMID: 30138686 DOI: 10.1016/j.jhep.2018.07.024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 13.5] [Reference Citation Analysis]
80 Otedo A, Simbiri KO, Were V, Ongati O, Estambale BA. Risk factors for liver Cancer in HIV endemic areas of Western Kenya.Infect Agent Cancer. 2018;13:41. [PMID: 30607173 DOI: 10.1186/s13027-018-0214-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 Kramer JR, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. J Acquir Immune Defic Syndr 2015;68:456-62. [PMID: 25559606 DOI: 10.1097/QAI.0000000000000494] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
82 Butt AA, Evans R, Skanderson M, Shakil AO. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol 2006;44:864-8. [PMID: 16516332 DOI: 10.1016/j.jhep.2006.01.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
83 Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-50. [PMID: 19889081 DOI: 10.1111/j.1478-3231.2009.02156.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
84 Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160:369-379. [PMID: 24723077 DOI: 10.7326/m13-1829] [Cited by in Crossref: 30] [Cited by in F6Publishing: 97] [Article Influence: 3.8] [Reference Citation Analysis]
85 Powles T, Macdonald D, Nelson M, Stebbing J. Hepatocellular cancer in HIV-infected individuals: tomorrow’s problem? Expert Review of Anticancer Therapy 2014;6:1553-8. [DOI: 10.1586/14737140.6.11.1553] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
86 Kramer JR, Giordano TP, El-Serag HB. Effect of human immunodeficiency virus and antiretrovirals on outcomes of hepatitis C: a systematic review from an epidemiologic perspective. Clin Gastroenterol Hepatol 2007;5:1321-1328.e7. [PMID: 17981246 DOI: 10.1016/j.cgh.2007.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
87 Gidding HF, Amin J, Dore GJ, Law MG. Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C. Epidemiol Infect 2011;139:1151-8. [DOI: 10.1017/s095026881000258x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
88 Halfon P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Cacoub P. Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV–Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study – ANRS HC02. Antiviral Therapy 2009;14:211-9. [DOI: 10.1177/135965350901400205] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
89 Marcon PDS, Tovo CV, Kliemann DA, Fisch P, Mattos AA. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study. World J Gastroenterol 2018; 24(5): 613-622 [PMID: 29434450 DOI: 10.3748/wjg.v24.i5.613] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
90 Beste LA, Green PK, Ioannou GN. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Eur J Gastroenterol Hepatol 2015;27:123-9. [PMID: 25503739 DOI: 10.1097/MEG.0000000000000241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
91 Pantanowitz L, Dezube BJ. Evolving spectrum and incidence of non-AIDS-defining malignancies. Curr Opin HIV AIDS. 2009;4:27-34. [PMID: 19339937 DOI: 10.1097/coh.0b013e32831a7259] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
92 Butt AA, Khan UA, Skanderson M. Comorbidities and Their Impact on Mortality in HCV and HCV-HIV–coinfected Persons on Dialysis. Journal of Clinical Gastroenterology 2008;42:1054-9. [DOI: 10.1097/mcg.0b013e3181574d58] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
93 Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. J Hepatol 2019;71:523-33. [PMID: 31145929 DOI: 10.1016/j.jhep.2019.05.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
94 Shetty V, Jain P, Nickens Z, Sinnathamby G, Mehta A, Philip R. Investigation of plasma biomarkers in HIV-1/HCV mono- and coinfected individuals by multiplex iTRAQ quantitative proteomics. OMICS 2011;15:705-17. [PMID: 21978398 DOI: 10.1089/omi.2011.0004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
95 Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013;57:249-57. [PMID: 22532055 DOI: 10.1002/hep.25800] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 15.6] [Reference Citation Analysis]
96 Lu M, Chacra W, Rabin D, Rupp LB, Trudeau S, Li J, Gordon SC. Validity of an automated algorithm using diagnosis and procedure codes to identify decompensated cirrhosis using electronic health records. Clin Epidemiol 2017;9:369-76. [PMID: 28744162 DOI: 10.2147/CLEP.S136134] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
97 Walker UA. Antiretroviral therapy-induced liver alterations. Curr Opin HIV AIDS 2007;2:293-8. [PMID: 19372901 DOI: 10.1097/COH.0b013e328122dbaa] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
98 Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009;23:875-85. [PMID: 19349851 DOI: 10.1097/QAD.0b013e328329216a] [Cited by in Crossref: 84] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
99 Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol. 2006;18:469-478. [PMID: 16894295 DOI: 10.1097/01.cco.0000239886.13537.ed] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 4.7] [Reference Citation Analysis]
100 Kowalkowski MA, Mims MP, Amiran ES, Lulla P, Chiao EY. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PLoS One 2013;8:e77409. [PMID: 24098586 DOI: 10.1371/journal.pone.0077409] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
101 Sigel K, Park L, Justice A. HIV and cancer in the Veterans Health Administration System. Semin Oncol 2019;46:334-40. [PMID: 31703932 DOI: 10.1053/j.seminoncol.2019.09.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
102 Lo Re V 3rd, Kostman JR, Amorosa VK. Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008;12:587-609, ix. [PMID: 18625430 DOI: 10.1016/j.cld.2008.03.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
103 Su F, Green PK, Berry K, Ioannou GN. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology 2017;65:426-38. [PMID: 27775854 DOI: 10.1002/hep.28901] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 11.4] [Reference Citation Analysis]
104 Kew MC, Smuts H, Stewart A. Does HIV Infection Enhance the Hepatocarcinogenic Potential of Chronic Hepatitis B Virus Infection? JAIDS Journal of Acquired Immune Deficiency Syndromes 2010;53:413-4. [DOI: 10.1097/qai.0b013e3181ba390f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Riedel DJ, Tang LS, Rositch AF. The role of viral co-infection in HIV-associated non-AIDS-related cancers. Curr HIV/AIDS Rep 2015;12:362-72. [PMID: 26152660 DOI: 10.1007/s11904-015-0276-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
106 Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008;22:203-10. [PMID: 18097222 DOI: 10.1097/QAD.0b013e3282f3553b] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
107 Benedetto ND, Peralta M, Alvarez E, Schroder MT, Estepo C, Paz S, Fainboim H. Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999-2011. Annals of Hepatology 2014;13:38-44. [DOI: 10.1016/s1665-2681(19)30902-0] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
108 Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17487 patients. Eur J Gastroenterol Hepatol. 2017;29:686-693. [PMID: 28195877 DOI: 10.1097/meg.0000000000000858] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
109 García-García JA, Romero-Gómez M, Girón-González JA, Rivera-Irigoin R, Torre-Cisneros J, Montero JL, González-Serrano M, Andrade RJ, Aguilar-Guisado M, Grilo I, Martín-Vivaldi J, Salmerón J, Caballero-Granado FJ, Macías J, Vergara-López S, Pineda JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas (GAEI)., Grupo Andaluz para el Estudio del Hígado (GAEH). Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis. AIDS Res Hum Retroviruses 2006;22:1236-41. [PMID: 17209765 DOI: 10.1089/aid.2006.22.1236] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]